Owner Scorecard


← All companies ← INVZ Manual IQ → ← IOVA Biotechnology IPSC →

IPHA, Innate Pharma S.A. ADS

Biotechnology consumer brand Unprofitable

The clinical studies of Innate's product candidates are and will be, subject to regulations by numerous government authorities in the United States, in the European Union and in other countries where the Company intends to test and, if approved, market any product candidate.

The research and development of pharmaceutical products is governed by complex regulatory requirements.

As the Company advances its product candidates, the Company will be required to consult with these regulatory agencies for regulatory approval and comply with all applicable guidelines, rules and regulations.

Latest annual: FY2025 20-F · figures as filed, in EUR · 1 ADS = 1 ordinary share
IPHA · Innate Pharma S.A. ADS
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
€9M
−55.2% YoY · −34% 5-yr CAGR
Vital signs · TTM
Cash & investments €34M
Cash burn · annual €53M
Runway 8 mo

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn.
What moves the needle
Operating margin has run around −91% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −1026%, above 15% in 1 of 3 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2017–2025

realized figures from each filing · older years to the left
2017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMDec 2025
Income statement
€44M€94M€85M€70M€25M€58M€62M€20M€9M€9MRevenueRevenue
(€40M)€5M€2M€1M(€48M)(€57M)(€13M)(€52M)(€54M)(€54M)Operating incomeOp. inc.
−90.8%5.5%1.8%1.5%−193.6%−99.6%−20.6%−256.3%−599.8%−599.8%Operating marginOp. mgn
(€48M)€3M(€21M)(€64M)(€53M)(€58M)(€8M)(€49M)(€49M)(€49M)Net incomeNet inc.
Cash flow & returns
(€48M)(€33M)€35M(€52M)(€58M)(€19M)(€33M)(€7M)(€53M)(€53M)Operating cash flowOp. cash
€4M€7M€14M€9M€5M€4M€5M€2M€1M€1MDepreciationDeprec.
(€4M)(€43M)€42M€3M(€10M)€35M(€30M)€41M(€5M)(€5M)Working capital & otherWC & other
€3M€873K€1M€907K€929K€535K€351K€391K€140K€140KCapexCapex
6.7%0.9%1.5%1.3%3.8%0.9%0.6%1.9%1.6%1.6%Capex / revenueCapex/rev
(€51M)(€33M)€34M(€53M)(€59M)(€20M)(€33M)(€7M)(€53M)(€53M)Owner earningsOwner earn.
−115.9%−35.6%39.4%−75.5%−240.4%−34.1%−53.4%−36.2%−587.4%−587.4%Owner earnings marginOE mgn
(€51M)(€33M)€34M(€53M)(€59M)(€20M)(€33M)(€7M)(€53M)(€53M)Free cash flowFCF
−115.9%−35.6%39.4%−75.5%−240.4%−34.1%−53.4%−36.2%−587.4%−587.4%Free cash flow marginFCF mgn
-41022%35%-1026%ROICROIC
-49%2%-10%-41%-49%-107%-15%-560%Return on equityROE
−49%2%−10%−41%−49%−107%−15%−560%Retained to equityRetained/eq
Balance sheet
€116M€168M€219M€152M€120M€101M€92M€81M€34M€34MCash & investmentsCash+inv
€21M€152M€19M€22M€18M€38M€56M€5M€12M€12MReceivablesReceiv.
€25M€92M€50M€30M€29M€21M€17M€16M€15M€15MAccounts payablePayables
(€3M)€60M(€31M)(€8M)(€10M)€17M€39M(€11M)(€3M)(€3M)Operating working capitalOper. WC
€138M€320M€238M€173M€138M€140M€148M€86M€47M€47MCurrent assetsCur. assets
€74M€197M€122M€45M€80M€41M€40M€33M€37M€37MCurrent liabilitiesCur. liab.
1.9×1.6×2.0×3.8×1.7×3.4×3.7×2.6×1.3×1.3×Current ratioCurr. ratio
€255M€451M€401M€307M€267M€199M€175M€111M€63M€63MTotal assetsAssets
(€116M)(€168M)(€219M)(€152M)(€120M)(€101M)(€92M)(€81M)(€34M)(€34M)Net debt / (cash)Net debt
-3.8×0.6×0.3×0.2×-12.0×-10.8×-6.9×-13.0×-17.3×-17.3×Interest coverageInt. cov.
€99M€167M€217M€156M€107M€54M€52M€9M(€22M)(€22M)Shareholders’ equityEquity
Per share
54.4M58.8M66.9M78.9M79.5M79.6M80.5M81.1M89.6M79.5MShares out (diluted)Shares
€0.81€1.60€1.28€0.88€0.31€0.72€0.77€0.25€0.10€0.11Revenue / shareRev/sh
€-0.89€0.05€-0.31€-0.81€-0.66€-0.73€-0.09€-0.61€-0.55€-0.62EPS (diluted)EPS
€-0.94€-0.57€0.50€-0.67€-0.75€-0.25€-0.41€-0.09€-0.59€-0.66Owner earnings / shareOE/sh
€-0.94€-0.57€0.50€-0.67€-0.75€-0.25€-0.41€-0.09€-0.59€-0.66Free cash flow / shareFCF/sh
€0.05€0.01€0.02€0.01€0.01€0.01€0.00€0.00€0.00€0.00Cap. spending / shareCapex/sh
€1.83€2.84€3.25€1.98€1.35€0.68€0.65€0.11€-0.24€-0.27Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
8-yr5-yr
Revenue / share−23.0%/yr−35.3%/yr
Capital spending / share−35.9%/yr−32.9%/yr

The record, charted

FY2017–2025

Each measure over its full record; the current point and the worst year marked.

Share count
90Mpeak FY2025
ROIC
−1026%low FY2017

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

(€53M)owner earningsvs.(€49M)net incomelow FY2021

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business reported a €49M loss but (€53M) of owner earnings: €4M less than the profit line, taken out by capital spending and the timing of cash.

FY2025FY2024FY2023FY2022FY2021
Reported net income(€49M)(€49M)(€8M)(€58M)(€53M)
Depreciation & amortizationnon-cash charge added back+€1M+€2M+€5M+€4M+€5M
Working capital & othertiming of cash in and out, other non-cash items−€5M+€41M−€30M+€35M−€10M
Cash from operations(€53M)(€7M)(€33M)(€19M)(€58M)
Capital expenditurecash put back in to keep running and to grow−€140K−€391K−€351K−€535K−€929K
Owner earnings(€53M)(€7M)(€33M)(€20M)(€59M)
Owner-earnings marginowner earnings ÷ revenue-587%-36%-53%-34%-240%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 20-F · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income (€54M) ÷ interest expense €3M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash, debt-free
    Cash €28M + ST investments €6M − debt €0
    What this means

    Cash and short-term investments exceed every dollar of debt by €34M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Not enough data
    Industry peers: median -152%
    What this means

    The filing data didn't include the inputs for this check.

  • Consumes cash through the cycle
    9-yr median margin, range -587%–39%; latest (€53M) = operating cash (€53M) − maintenance capex €140K
    Industry peers: median -1295%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -587% of revenue this year, a -53% median across 9 years.

  • Loss, and burning cash
    Net income (€49M) · cash from operations (€53M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 0.10×
    Harvesting
    Capex €140K ÷ depreciation €1M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 0 of 3 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size
    Revenue ≥ $2B (a dollar floor) · €9M
    What this means

    Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.

  • Strong liquidity Miss
    Current ratio ≥ 2× · 1.27×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Earnings stability Miss
    A profit every year (9-yr record) · 8 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · none paid
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are €-0.38/share (latest year €-0.52), the averaged base the calculator's gate runs on, and book value is €-0.23/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2017–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 1 of 9
    What this means

    Lost money in 8 year(s), look at what happened there before trusting the average.

  • Operating margin −28% → −292% (3-yr avg ends)
    What this means

    Through the cycle the operating margin slipped — about −28% early to −292% lately, median −91% — competition or costs are biting in.

  • Worst year 2025 · −599.8% op. margin
    What this means

    Operations went underwater in 2025, understand why before trusting the good years.

  • Share count +6.4%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of fiscal year-end, Dec 31, 2025

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets€47M
  • Cash & short-term investments€34M
  • Receivables€12M
Current liabilities€37M
  • Accounts payable€15M
  • Other current liabilities€22M
Current ratio1.27×all current assets ÷ what's due · Graham looked for 2×
Quick ratioinventory untagged this quarter, so withheld rather than shown equal to the current ratio
Cash ratio0.94×strictest: cash alone against what's due
Working capital€10Mthe cushion left after near-term bills
Cash runway0.6 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Deeper floors
Tangible book value(€22M)equity stripped of goodwill & intangibles
Debt incl. operating leases€3M€3M of it operating leases

From the company's latest filing.

Peers, Biotechnology

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
RLAYRelay Therapeutics Inc.$15M-2846.8%-46%-2023%
ACOGAlpha Cognition Inc.$10M-221.7%-200%
TSHATaysha Gene Therapies Inc.$10M-1114.1%-970%
PRTAProthena Corporation plc$10M-1390.3%-1090%
IPHAInnate Pharma S.A. ADS€9M-90.8%-1026%-53%
SLDBSolid Biosciences Inc.$8M-2214.1%-152%-1945%
DBVTDBV Technologies S.A.$6M-1727.6%-1206%-1493%
OCGNOcugen Inc.$4M-1425.7%-1295%
Group median-1408.0%-589%-1193%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Enter the US price, in dollars: the NYSE/Nasdaq quote you hold. Per the filing's own cover, “American Depositary Shares, each representing one ordinary”; Innate Pharma S.A. ADS reports in EUR, so every figure in this tool is stated per ADS and translated at EUR 1 = $1.145 (2026-07-17, reference rate) so your dollar quote reconciles exactly. The record tables elsewhere on this page remain as filed, in EUR.

Innate Pharma S.A. ADS is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered−27%/yr’20→’25

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−587%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Innate Pharma S.A. ADS (IPHA), the owner's record," https://ownerscorecard.com/c/IPHA, data as of 2026-07-09.

Manual order: ← INVZ its page in the Manual IQ →

Industry order: ← IOVA the Biotechnology chapter IPSC →